Physiological Profile and Limitations in Exercise in Idiopathic Pulmonary Fibrosis

被引:8
|
作者
Vainshelboim, Baruch [1 ,2 ]
Oliveira, Jose [2 ]
Fox, Benjamin Daniel [1 ,3 ]
Adir, Yochai [4 ]
Ollech, Jacob Eliezer [1 ]
Kramer, Mordechai Reuven [1 ,3 ]
机构
[1] Beilinson Med Ctr, Pulm Inst, Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel
[2] Univ Porto, Res Ctr Phys Act Hlth & Leisure CIAFEL, Fac Sport, Oporto, Portugal
[3] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[4] Technion Israel Inst Technol, Lady Davis Carmel Med Ctr, Fac Med, Div Pulm, Haifa, Israel
关键词
aerobic exercise capacity; cardiopulmonary exercise test; functional capacity; idiopathic pulmonary fibrosis; 6-minute walk test; INTERSTITIAL LUNG-DISEASE; 6-MINUTE WALK; REHABILITATION; CAPACITY; STANDARDIZATION; RECOMMENDATIONS; GUIDELINES; STATEMENT; DIAGNOSIS; MORTALITY;
D O I
10.1097/HCR.0000000000000177
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: This study aimed to describe the physiological profile and limiting factors during exercise among patients with idiopathic pulmonary fibrosis. METHODS: A descriptive study involving 34 patients with idiopathic pulmonary fibrosis (22 men) aged 68 +/- 8 years was conducted. All patients completed a pulmonary function test, cardiopulmonary exercise test, Doppler echocardiography, 6-minute walk test, and modified Medical Research Council dyspnea evaluation. RESULTS: Approximately 38% of patients (range, 15%-71%) presented with coexisting comorbidities including pulmonary hypertension and emphysema. Modified Medical Research Council grades 0-2 and 3-4 were assigned to 68% and 32% of patients, respectively. Median values for forced vital capacity and diffusion capacity for carbon monoxide percent (%) predicted were 68 (95% CI, 63-76) and 51 (95% CI, 46-55), respectively. Left ventricular systolic function was normal. Aerobic capacity ((V)Over dotO(2peak) = 13.4 mL/kg/min [95% CI, 12.6-14.9]; 62% predicted [95% CI, 56-67]) was moderately reduced with the presence of abnormalities in pulmonary gas exchange and desaturation, circulatory impairments, inefficient ventilation, and skeletal muscle dysfunction. Functional capacity was normal (6-minute walk test distance = 505 m [95% CI, 435-522]; 99% predicted [95% CI, 91-108]). CONCLUSIONS: The physiological profile demonstrated the presence of comorbidities in approximately 38% of patients with idiopathic pulmonary fibrosis and a moderate level of dyspnea. Resting cardiopulmonary function showed moderate pulmonary restriction and severe impairments in diffusion capacity with normal left ventricular systolic function. Multifactorial limitations for a moderately diminished aerobic capacity were revealed during the cardiopulmonary exercise test, although functional capacity was normal. These results emphasize the significance of a meticulous evaluation, including the cardiopulmonary exercise test for an accurate exercise tolerance evaluation, to aid in the diagnosis and prognosis and for developing effective targeted treatments.
引用
收藏
页码:270 / 278
页数:9
相关论文
共 50 条
  • [31] Characteristic of four exercise tests in patients with idiopathic pulmonary fibrosis
    Arizono, Shinichi
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Ogawa, Tomoya
    Watanabe, Fumiko
    Tawara, Yuichi
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [32] The Prognostic Value of Cardiopulmonary Exercise Testing in Idiopathic Pulmonary Fibrosis
    Fell, Charlene D.
    Liu, Lyrica Xiaohong
    Motilka, Caroline
    Kazerooni, Ella A.
    Gross, Barry H.
    Travis, William D.
    Colby, Thomas V.
    Murray, Susan
    Toews, Galen B.
    Martinez, Fernando J.
    Flaherty, Kevin R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179 (05) : 402 - 407
  • [33] Correction to: Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use
    Katherine A. Lyseng-Williamson
    Drugs & Therapy Perspectives, 2018, 34 (8) : 404 - 404
  • [34] Comment on: ‘Pirfenidone Tablets in Idiopathic Pulmonary Fibrosis: A Profile of Their Use’
    Susanne Stowasser
    Manuel Quaresma
    Markus Rieck
    Drugs & Therapy Perspectives, 2018, 34 (4) : 192 - 193
  • [35] Prognostic value of clinical exercise testing in idiopathic pulmonary fibrosis
    Wallaert, B.
    Guetta, A.
    Wemeau-Stervinou, L.
    Terce, G.
    Valette, M.
    Neviere, R.
    Aguilaniu, B.
    REVUE DES MALADIES RESPIRATOIRES, 2011, 28 (03) : 290 - 296
  • [36] Exercise Testing in Idiopathic Pulmonary Fibrosis: Expanding Our Options
    Mura, Marco
    Bouros, Demosthenes
    RESPIRATION, 2021, 100 (07) : 568 - 570
  • [37] Exercise-induced cough in patients with idiopathic pulmonary fibrosis
    Polastri, Massimiliano
    Bandelli, Gian Piero
    CLINICAL RESPIRATORY JOURNAL, 2021, 15 (08): : 925 - 926
  • [38] Comment on: 'Pirfenidone Tablets in Idiopathic Pulmonary Fibrosis: A Profile of Their Use'
    Stowasser, Susanne
    Quaresma, Manuel
    Rieck, Markus
    DRUGS & THERAPY PERSPECTIVES, 2018, 34 (04) : 192 - 193
  • [39] Benefits of pulmonary rehabilitation and predictor of changes in exercise capacity for idiopathic pulmonary fibrosis
    Mishima, Takuya
    Ogawa, Tomoya
    Watanabe, Fumiko
    Hirasawa, Jun
    Takurou, Furukawa
    Tanaka, Yuko
    Shingai, Kazuya
    Nagae, Yusuke
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Arizono, Shinichi
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [40] Sildenafil to Increase Exercise Capacity in Individuals with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension
    不详
    PHYSICIAN AND SPORTSMEDICINE, 2009, 37 (01): : 8 - 8